Janssen announces Health Canada approval of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are transplant ineligible

Janssen

30 October 2019 - This Darzalex combination regimen reduced the risk of disease progression or death by 44% in newly diagnosed patients who are transplant ineligible.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada recently approved under Priority Review Darzalex (daratumumab), in combination with lenalidomide and dexamethasone (Rd), for newly diagnosed patients with multiple myeloma who are ineligible for autologous stem cell transplant. 

The approval is based on results from the Phase 3 MAIA clinical study published in the New England Journal of Medicine, which showed the Darzalex-Rd combination reduced the risk of disease progression or death by 44% compared to treatment with Rd alone.

Read Janssen press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Canada